Valsecchi ME, et al. - This trial undertook a comparative inspection of the overall survival in high-risk patients with primary uveal melanoma, who received adjuvant sunitinib with institutional controls. The findings underscored the correlation between the use of sunitinib in the adjuvant setting with better overall survival.